My watch list
my.chemeurope.com  
Login  

Ranbaxy's Toansa plant receives national awards for excellence in water management

03-01-2006: Ranbaxy Laboratories Limited (RLL) announced that the Company's manufacturing plant at Toansa (Punjab, India) received the following 2 prestigious national awards for excellence in water management: National Award for Excellence in Water Management 2005 as an `Excellent Water Efficient Unit' amd National Award for Excellence in Water Management 2005 as `Most Useful Presentation'.

The recognition is reflective of Ranbaxy's commitment to embrace stringent Environment and Quality Management standards.

75 Medium and Large Scale Companies from all over India, had participated in the Competition of which 14 companies including Ranbaxy emerged as winners and were honoured with the Award for `Excellent Water Efficient Units'. Selection of the 'Most Useful Presentation' was on the basis of feedback from participants (approx. 75 Nos.) at the National Competition.

Ranbaxy prides itself on managing its operations with a high level of concern for Environment, Health & Safety (EH&S). The Company's manufacturing facilities have Effluent Treatment Systems/ Plants (ETP's) from the time of its operation and the Toansa plant has ETP systems since its inception in 1986. The Company has invests substantially in the up-gradation and maintenance of its ETP. As a testimony to the purity of the treated water the Company has fish ponds in place where aquatic life continue to flourish.

Facts, background information, dossiers
More about Ranbaxy
  • News

    Ranbaxy to acquire the unbranded generic business of GlaxSmithKline in Italy

    Ranbaxy Laboratories Limited announced that the Company will acquire the unbranded generic business of Allen S.p.A, a division of GlaxoSmithKline (GSK), in Italy, through Ranbaxy's Italian subsidiary, Ranbaxy Italia S.p.A.. The deal will come into effect from April 01, 2006. Commenting on ... more

    Pfizer Prevails in Norwegian Lipitor Patent Challenge

    Pfizer Inc said that the Oslo District Court in Norway ruled that a Pfizer patent covering an intermediate compound used to make atorvastatin, the active ingredient in Lipitor, would be infringed by the sale of Ranbaxy Laboratories Ltd.'s proposed generic atorvastatin product in Norway. In ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE